The U.S. Department of Health and Human Services said on Tuesday it was setting most-favored-nation prescription drug pricing targets following an executive order from President Donald Trump last week aimed at lowering the prices of branded medicines for U.S. consumers. HHS wants U.S. prescription drug prices to drop to the lowest possible price among countries that are members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. The new pricing targets would focus on OECD nations that have a gross domestic product per capita of at least 60% of U.S. per-capita GDP, the department said.

The U.S. Department of Health and Human Services said on Tuesday it would set drug prices pegged to the lowest level paid by other high-income countries following an executive order from President Donald Trump last week aimed at lowering the prices of branded medicines for U.S. consumers. HHS wants to implement so-called most-favored-nation pricing under which U.S. prescription drug prices would drop to the lowest possible price paid by countries that are members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies.

The US Department of Health and Human Services says its is setting most-favoured-nation prescription drug pricing targets following an executive order from President Donald Trump last week aimed at lowering the prices of branded medicines for US consumers. HHS wants US prescription drug prices to drop to the lowest possible price among countries that are members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. The new pricing targets would focus on OECD countries that have a gross domestic product per capita of at least 60 per cent of US per-capita GDP, the department said.

The Department of Health and Human Services will aim to negotiate drug prices down to the lowest prices paid by peer nations. The pricing targets will apply to brand-name drugs that don't face competition from generics or biosimilars. The announcement offers new details about the sweeping executive order signed by President Trump last week.

Health Secretary Robert F Kennedy Jr to reveal specific targets for companies in coming weeks*Most-favored-nation pricing could alter global drug market…